All In Biotech

Free tool

FAERS Monitor: Brenzavvy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214373 or its brand name (Brenzavvy, Bexagliflozin). Reports on generic versions are filed under their own applications.

Reports

31

Serious

12

39% of reports

Hospitalization

3

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache7
  • weight decreased7
  • fatigue6
  • nausea6
  • cough5
  • decreased appetite5
  • asthenia4
  • chest discomfort4
  • dyspnoea4
  • gastrointestinal disorder4
  • oropharyngeal pain4
  • throat irritation4
  • throat tightness4
  • abdominal pain upper3
  • blood glucose increased3

Reports by year received

View as table
YearReports
20231
20246
202514
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,128 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
throat tightnessSignal4100.440.2301
throat irritationSignal460.524.2179
gastrointestinal disorderSignal430.312.186
oropharyngeal painSignal429.311.783
chest discomfortSignal426.510.675
weight decreasedSignal717.08.991
decreased appetiteSignal514.66.551
coughSignal512.15.441
blood glucose increasedSignal310.83.718
abdominal pain upperSignal39.93.416
headacheSignal77.63.935
astheniaSignal47.22.916
fatigueSignal65.22.517
nauseaSignal65.12.517
dyspnoeaSignal44.81.99

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.